Abstract Purpose: Elevated proportions of regulatory T cells (T reg ) are present in patients with a variety of cancers, including malignant glioma, yet recapitulative murine models are wanting. We therefore examinedT regs in mice bearing malignant glioma and evaluated anti-CD25 as an immunotherapeutic adjunct. + T cells, despite themselves being reduced in number. Similar trends are observed in cervical lymph node and spleen, but not in bone marrow. Systemic anti-CD25 administration hinders detection of CD25 + cells but fails to completely eliminate T regs , reducing their number only moderately, yet eliminating their suppressive function. This elimination of T reg function permits enhanced lymphocyte proliferative and IFN-g responses and up to 80% specific lysis of glioma cell targets in vitro. When combined with dendritic cell immunization, anti-CD25 elicits tumor rejection in 100% of challenged mice without precipitating experimental allergic encephalitis. Conclusions: Systemic anti-CD25 administration does not entirely eliminateT regs but does prevent T reg function. This leads to safe enhancement of tumor immunity in a murine glioma model that recapitulates the tumor-induced changes to the CD4 and T reg compartments seen in patients with malignant glioma.
+ T regs represent an increased fraction of the remaining peripheral blood CD4 + T cells, despite themselves being reduced in number. Similar trends are observed in cervical lymph node and spleen, but not in bone marrow. Systemic anti-CD25 administration hinders detection of CD25 + cells but fails to completely eliminate T regs , reducing their number only moderately, yet eliminating their suppressive function. This elimination of T reg function permits enhanced lymphocyte proliferative and IFN-g responses and up to 80% specific lysis of glioma cell targets in vitro. When combined with dendritic cell immunization, anti-CD25 elicits tumor rejection in 100% of challenged mice without precipitating experimental allergic encephalitis. Conclusions: Systemic anti-CD25 administration does not entirely eliminateT regs but does prevent T reg function. This leads to safe enhancement of tumor immunity in a murine glioma model that recapitulates the tumor-induced changes to the CD4 and T reg compartments seen in patients with malignant glioma.
It is currently well established that the peripheral CD4
+ T-cell repertoire is equipped with its own means for the enforcement of tolerance (1 -9) . Focused within the CD25 + GITR + Foxp3 + compartment (10, 11) , this regulatory T-cell constituent (T reg ) also seems to play a significant role in hindering immunity to tumor antigens (12, 13) . Accordingly, T regs come to represent an increased fraction of CD4 + T cells in the peripheral blood or tumor of patients with a variety of malignancies (13 -16) . Recent work also indicates that such increased ''T reg fractions'' exist amidst severe CD4 lymphopenia in patients harboring malignant glioma (17) and assume responsibility for cellular immune defects described for these patients over the last three decades (reviewed in ref. 18) . Therefore, provided an appropriate, recapitulative murine model of malignant glioma, targeting T reg activity could gain justification as a means to counter immunosuppression and enhance antitumor immune responses in these patients. This strategy currently remains untested in brain tumor models.
We report here that our murine model of glioma indeed recapitulates malignant glioma -induced changes to the human peripheral blood CD4 and T reg compartments. Specifically, tumor-bearing mice exhibit CD4 lymphopenia whereas CD4 + CD25 + Foxp3 + GITR + T regs come to represent an increased fraction of the peripheral blood CD4 + T cells that remain despite themselves being reduced in number. Extending the study to other sites, similar phenomena are observed in the spleens and cervical lymph nodes whereas the reverse scenario emerges in bone marrow. We employed this model to investigate the in vivo effects of T reg removal on antiglioma immune responses. The current doctrine is that effective depletion of T regs may be achieved simply by systemic administration of anti-CD25 monoclonal antibody (mAb; refs. 19 -21) . Likewise, in non -central nervous system (CNS) tumor models, the administration of anti-CD25 mAb has been employed in attempts to remove T regs and has effectively elicited prolonged survival to s.c. tumor challenge (22 -24) . These studies, however, predated our ability to examine Foxp3 expression in T regs with antibody staining.
Following in vivo administration of anti-CD25 mAb, we discovered that CD4 + Foxp3 + GITR + cells failed to entirely disappear despite the present thinking. Instead, they persisted at significant levels in all sites tested. When isolated based on CD4 and glucocorticoid-induced tumor necrosis factor -like receptor (GITR) expression, however, these cells showed none of the typical suppressive capacities of CD4 + CD25
+ GITR + T regs in vitro. Accordingly, systemic anti-CD25 mAb proved capable of enhancing T-cell proliferation, IFN-g production, and glioma-specific CTL responses in treated mice. When combined with a dendritic cell -based immunization strategy, anti-CD25 mAb elicited glioma rejection in 100% of challenged mice without attendant induction of experimental allergic encephalitis. Systemic anti-CD25 mAb administration therefore seems to counter the suppressive effects of T regs without comprehensively eliminating the cells in vivo. This activity proves permissive for potent antitumor immunity in a murine glioma model that aptly recapitulates tumor-induced changes to the CD4 and T reg compartments.
Materials and Methods
Tumor cell line and experimental animals. The SMA-560 cell line was derived from a spontaneous intracerebral malignant glioma arising in inbred VM/Dk mice. VM/Dk mice were obtained from the McLaughlin Research Institute (Great Falls, MT) and an inbred colony was established at Duke University. Mice are maintained in a pathogenfree environment.
Antibodies. Antibodies to CD3 (145-2C11), CD4 (L3T4), CD16/32 (2.4G2), CD25 (PC61 and 7D4), and rat immunoglobulin G1 (IgG1) and appropriate isotype controls were obtained from BD PharMingen (San Diego, CA). Anti-a-GITR (108619) was obtained from R&D Systems (Minneapolis, MN) and a-Foxp3 (FJK-16s) was obtained from eBioscience (San Diego, CA). Anti-CD25 (PC61) ascites for in vivo administration was obtained from Accurate Chemical (Westbury, NY).
Flow cytometry. Spleens and cervical lymph nodes were harvested, minced, and pushed through cell screens to create single-cell suspensions. Whole blood was obtained by retro-orbital bleed. Bone marrow was harvested from tibias. RBC lysis was done on spleens, bone marrow, and whole blood as needed with 1Â ammonium chloride lysing solution (BD PharMingen). Cells were incubated first with antibodies against surface markers for 30 minutes at 4jC in the dark. Cells were fixed and permeabilized using 1Â Fix/Perm solution (eBioscience) according to the instructions of the manufacturer. Following incubation period, cells were washed in 1Â Permeabilization Buffer (eBioscience), Fc-blocked with a-CD16/32, and stained with a-Foxp3 for 30 minutes at 4jC in the dark. Cells were washed, fixed, and analyzed on a FACSVantage SE or LSRII flow cytometer (BD Biosciences).
Isolation of T cells and T regs . IFN-g ELISA. Experimental supernatants were assayed for IFN-g levels using eBioscience IFN-g ELISA sets (eBioscience) according to the instructions of the manufacturer. Briefly, ELISA plates were coated with capture antibody and incubated overnight at 4jC. The following day, wells were washed and blocked before addition of standards and samples to the appropriate wells. Plates were later incubated with detection antibody and detected with avidin-horseradish peroxidase, followed by addition of substrate and stop solutions. Plates were read at 450 nm.
Generation of murine bone marrow -derived dendritic cells. Tibias, femurs, and sternums were removed using sterile technique and marrow was harvested. RBCs were lysed with ammonium chloride. Cells were suspended in complete dendritic cell medium and plated in six-well plates. Dendritic cell medium consists of T-cell medium + 18 ng/mL murine granulocyte-macrophage colony-stimulating factor (Peprotech, Rocky Hill, NJ) + 18 ng/mL murine interleukin 4 (Peprotech). Medium was replaced on day 3. On day 7, nonadherent cells were collected and replated. On day 8, nonadherent cells were harvested and electroporated with total tumor RNA isolated from the SMA-560 glioma cell line using RNeasy Midi Kit (Qiagen, Valencia, CA) at 300 V Â 500 As using an ECM 830 electroporator (BTX, San Diego, CA). On day 9, nonadherent cells were harvested for use in vaccines.
CTL assay. Target cells (5 Â 10 6 -10 Â 10 6 ) were labeled with europium for 20 minutes at 4jC. Europium-labeled targets (10 4 ) and serial dilutions of effector cells at varying effector/target ratios were incubated in T-cell medium for 4 hours. Supernatant was harvested and europium release was measured by time-resolved fluorescence. Specific cytotoxic activity was determined using the following formula: % specific release = [(experimental release À spontaneous release) / (total release À spontaneous release)] Â 100. Spontaneous release of the target cells was <25% of total release by detergent in all assays. SE of triplicate cultures was <5%.
Intracranial tumor challenge. Tumor cells were harvested, mixed with an equal volume of 10% methylcellulose in PBS, and loaded into 250-AL Hamilton syringes (Hamilton, Reno, NV). Mice (VM/Dk or athymic BALB/c) were anesthetized with a mixture of xylazine/ketamine and placed into a stereotactic frame (Kopf Instruments, Tujunga, CA). The injection needle was positioned 2 mm to the right of bregma and 4 mm below the surface of the skull. Cells Statistical analysis. Unless otherwise stated, comparisons of T-cell numbers, T reg fractions, and proliferation levels among groups were made using unpaired t tests. To compare lysis curves generated in CTL assays, a generalized linear model for normal data that accounted for correlation of measurement replication within groups was used. Survival estimates and median survivals were determined using the method of Kaplan and Meier. Survival curves for each group were compared using the log-rank test.
Results
Validation of T reg phenotype and function in normal and tumor-bearing mice. T regs were defined phenotypically as CD4 + T cells coexpressing the surface markers CD25 and GITR, as well as the intracellular T reg -specific transcription factor forkhead box p3 (Foxp3). Using flow cytometry, we validated that Foxp3 was found specifically within those CD4 + T cells expressing both CD25 and GITR. A representative analysis is depicted in Fig. 1A To obtain functional validation then, CD4 + CD25 + GITR + T cells present in both naBve and tumor-bearing mice were sorted and tested in standard in vitro assays. We confirmed that CD4 + CD25 + GITR + T cells in both naBve and tumor-bearing mice were anergic to T-cell receptor stimulation and exhibited a dose-dependent capacity to suppress the proliferation of surrounding CD4 + CD25
À T cells.
To this end, CD4 + T cells were enriched through negative selection (leaving the CD4 molecule untouched) and were sorted into CD25 + GITR + and CD25 À populations. The abilities of each population to proliferate in response to anti-CD3 F anti-CD28 mAbs were tested, and whereas CD4 + CD25 À cells in all instances proliferated well, CD4 + CD25 + GITR + cells from tumor-bearing mice failed to respond, in a manner identical to those isolated from naBve mice (Fig. 1C) À cells (Fig. 1D ).
The use of a fixed number of responders in these assays ruled out the prospect of a dilutional effect due to addition of nonresponsive T regs and likewise indicated true suppressive activity.
Alterations to the T reg and CD4 compartments in mice bearing glioma. Patients with malignant glioma show a markedly increased T reg fraction in their peripheral blood, which serves to hinder their cellular immune responses (17) . We therefore evaluated the T reg fraction in mice harboring intracranial SMA-560 glioma. T reg fraction was defined a priori as the percentage of CD4 + T cells coexpressing CD25, GITR, and Foxp3. In addition to peripheral blood, however, T reg fraction was also analyzed in the cervical lymph nodes, spleens, and bone marrow of naBve VM/Dk mice, as well as of VM/Dk mice implanted intracranially 21 days earlier with 10,000 SMA-560 glioma cells. Median survival following this manner of implantation is typically 24 to 27 days (data not shown).
The T reg fraction assessed in the peripheral blood of naBve mice was 2.61 F 0.17% of CD4 + T cells (mean F SE; n = 10). In VM/Dk mice bearing malignant glioma, however, this fraction was raised by 65% to 4.31% F 0.34% (n = 10, P = 0.0004; Fig. 2A ). Elevations in T reg fraction were also found in the cervical lymph nodes of tumor-bearing mice ( Fig. 2A) . As tumors were implanted within the right cerebral hemisphere, however, T reg fractions in the ipsilateral (right) and contralateral (left) cervical lymph nodes were measured individually. In general, T regs represented a larger proportion of CD4 + T cells in cervical lymph nodes than in peripheral blood (mean T reg fraction in cervical lymph nodes of naBve mice was 9.51 F 0.26%, n = 20, versus 2.61% F 0.17% in peripheral blood, P < 0.0001). As expected, no significant differences were observed between the left and right cervical lymph nodes of naBve mice (P = 0.548). Whereas the T reg fraction was elevated bilaterally in the cervical lymph nodes of tumor-bearing mice relative to naBve mice, however ( Fig. 2A) , in tumor-bearing mice this elevation was significantly higher within ipsilateral nodes, where T reg fraction reached as high as 37% (mean, 21.94 F 2.67%; P = 0.011). A representative staining from the ipsilateral cervical lymph nodes is depicted in Fig. 2B . In the spleen, a small but nonsignificant increase in T reg fraction was also observed among mice bearing tumor (naBve, 9.83 F 1.02%; tumor-bearing, 10.83 F 1.30%; P = 0.567; Fig. 2A ).
Interestingly, whereas increases in T reg fraction were observed in the tissues above, a decrease in T reg fraction was observed within the bone marrow of mice bearing glioma. Notably, in naBve mice, T regs represented a disproportionately large percentage of CD4 + T cells present (mean, 40.70 F 1.07%) as compared with the other sites evaluated. In tumor-bearing mice, however, this value dropped precipitously, such that T regs came to represent only 16.92 F 3.42% of CD4 + T cells (P = 0.0021; Fig. 2A) . A representative analysis of bone marrow is depicted in Fig. 2C .
We also sought to determine the relative presence of T regs at the tumor site in mice with glioma. To this end, SMA-560 tumors were isolated from VM/DK mice 21 days following + cells were found exclusively within the tumors of immunocompetent mice, confirming a T reg infiltration of murine gliomas (Fig. 2D) .
In patients with malignant glioma, increases in the peripheral blood T reg fraction exist amidst a dramatic CD4 lymphopenia. Consequently, the absolute number of peripheral blood T regs in these patients is actually reduced (17) . We therefore assessed the absolute CD4 and T reg counts in the peripheral blood, cervical lymph node, spleen, and bone marrow of glioma-bearing (day 21) versus naBve mice. Complete blood cell, total cervical lymph node cell, total splenocyte, and total tibial bone marrow cell counts were determined and cells were subjected to flow cytometric analysis. Live-cell and lymphocyte gates were created on forward and side scatter plots and the percentages of cells that represented viable CD3 + , CD3 + CD4 + , and CD4 + CD25 + Foxp3 + GITR + lymphocytes were subsequently determined. These percentages were multiplied by total cell counts to determine absolute counts of the respective cells and these counts were compared among groups.
As may be observed in Fig. 3A and Table 1 , the presence of SMA-560 within the intracranial compartment elicited dramatic reductions in the number of CD4 + T cells in both the ipsilateral and contralateral cervical lymph nodes (P = 0.001 and P = 0.002, respectively). This was especially pronounced in the ipsilateral cervical lymph nodes (P = 0.014 for comparison with contralateral cervical lymph nodes). Similar decreases were also present in the spleen and peripheral blood.
Absolute counts of T regs were subsequently quantified in the same locations. Despite representing an increased fraction of CD4 + T cells in both the peripheral blood and cervical lymph nodes of tumor-bearing mice ( Fig. 2A) , T regs in these mice were reduced in absolute number at each site (Fig. 3B) . The decreases in the cervical lymph nodes were significant (ipsilateral, Fig. 1 Research.
on April 14, 2017. © 2006 American Association for Cancer clincancerres.aacrjournals.org Downloaded from P < 0.0001; contralateral, P < 0.0001). In the spleens of gliomabearing mice, where T regs had not exhibited a significantly increased representation among CD4 + T cells ( Fig. 2A) , absolute reductions were also present and were indeed significant (naBve, 2,113,465 F 90,120; tumor-bearing, 433,099 F 105,100; P < 0.0001; Fig. 3B ). At none of the above sites then were T regs observed to have actually expanded in number in the tumor-bearing state.
Interestingly, the opposite scenario was observed in the bone marrow. Although no significant differences in total bone marrow cell counts were observed among naBve and tumorbearing mice (P = 0.3118; data not shown), CD4 + T cells came to be present at both increased percentages [P = 0.0024; observed in Fig. 2C (left) ] and increased numbers (P = 0.002; Fig. 3C ) in the marrow of mice harboring glioma. These increases were dramatic, approaching and exceeding 400%, respectively. Accordingly, despite exhibiting diminished T reg fractions in the bone marrow, glioma-bearing mice showed a nearly 70% increase in the absolute number of T regs present in this compartment (P = 0.011; Fig. 3C) . A more striking and disproportionate increase, however, was thus observed in the absolute number of CD4 + CD25 À cells, which were expanded >6-fold in the marrow of tumor-bearing mice (P = 0.002; Fig. 3C ). Therefore, whereas CD4 + T cells and T regs were found to be reduced in absolute number in the peripheral blood, cervical lymph nodes, and spleen of tumor-bearing mice, these cells were conversely found at greater numbers in the bone marrow of the same animals.
Administration of anti-CD25 in vivo disrupts T reg function without eliciting a complete T reg depletion. Given the ability of T regs to influence immune responses in patients with malignant glioma, we wished to evaluate the effects of in vivo anti-CD25 administration on immune responses in our recapitulative murine model. It has been widely supposed, including by us, that administration of anti-CD25 antibody in vivo results in the long-lived depletion of CD25 + T regs , thus permitting enhanced T-cell responses (19) . The availability of mAbs to Foxp3, however, now permits us to more closely follow the fate of T regs ) in peripheral blood, cervical lymph nodes, spleen, and bone marrow of naI« ve mice (n = 10) and mice with intracranial glioma (tumor-bearing; n = 10). Significant elevations are found in the blood (P = 0.0004), ipsilateral cervical lymph nodes (P = 0.01), and contralateral cervical lymph nodes (P = 0.008) of tumor-bearing mice. Furthermore, within tumor-bearing mice, ipsilateral cervical lymph nodes exhibit a higherT reg fraction than contralateral cervical lymph nodes (P = 0.011). In contrast, a decrease inT reg fraction was observed within the bone marrow of tumor-bearing mice (P = 0.0021). Columns, mean; bars, SE. Comparisons between groups were made using unpaired t tests. B, representative analysis of CD25, Foxp3, and GITR levels in ipsilateral (right) cervical lymph nodes isolated from naI« ve (N) and tumor-bearing (TB) mice. Left, gated on CD4 + lymphocytes and depict CD4 Â CD25 staining. Middle, levels of in mice following administration of anti-CD25. Accordingly, we examined the time course of CD4, CD25, Foxp3, and GITR levels in mice given a single i.p. injection of anti-CD25 (PC61) mAb. We found, in agreement with very recent work by Kohm et al. (25) , that anti-CD25 may not work entirely by eliminating T regs , as originally thought.
Following administration of 0.5 mg anti-CD25 ascites (PC61), VM/Dk mice were sacrificed at various time points, and the levels of CD4 + CD25 + and CD4 + Foxp3 + GITR + cells assessed independently by flow cytometry. Measurements were taken in the peripheral blood, cervical lymph node, spleen, and bone marrow. As may be observed in Fig. 4A , CD25 (PC61) became rapidly undetectable on the surface of cells at all sites following antibody administration and levels did not begin to recover for f40 days.
In contrast, in the days following anti-CD25 administration, CD4 + Foxp3 + GITR + T cells remained detectable at all sites evaluated (Fig. 4A) . A moderate decrease in their levels was observed over time, and this change generally reached a plateau before a gradual recovery initiated. These results suggested to us NOTE: Differences at all sites measured are significant as indicated by the included P values. Additionally, differences between ipsilateral and contralateral cervical lymph nodes within tumor-bearing mice are significant (P = 0.014), with ipsilateral cervical lymph nodes showing greater reduction in counts.
Fig. 3. Absolute CD4 and T reg counts.
A and B, counts in cervical lymph node, spleen, and peripheral blood. Absolute counts of CD4 + Tcells (A) andT regs (B) are shown for the cervical lymph nodes (left), spleens (left), and peripheral blood (right) of tumor-bearing versus naI« ve mice. At these sites, CD4 counts were dramatically reduced (seeTable 1). T regs , despite generally representing an increased percentage of CD4 + Tcells in these locations, were also typically reduced in number. Decreases in the ipsilateral cervical lymph nodes, contralateral cervical lymph nodes, and spleen of tumor-bearing mice were significant when compared with the same sites in naI« ve mice using unpaired t tests (P < 0.0001for each location). C, CD4 and T reg counts in bone marrow. Unlike the situation at other sites, both CD4 + Tcells (P = 0.002) andT regs (P = 0.011) were found in greater numbers within the bone marrow of tumor-bearing mice. T regs increased their presence by f70% despite representing a dramatically reduced fraction of CD4 + Tcells. This contrast may be explained by the >6-fold increase in CD4 + CD25 À T-cell counts (P = 0.002) in the bone marrow of glioma-bearing mice, also depicted in (C). 
GITR
+ cells had instead arisen de novo. To examine this further, however, we analyzed the levels of CD4, Foxp3, GITR, and two epitopes of CD25 (PC61 and 7D4) present in the lymphocytes of mice in the minutes and hours immediately following in vivo PC61 administration. Furthermore, as the administered PC61 antibody is a rat IgG1 isotype, we assessed the levels of rat IgG1 present on the surface of cells over the same time periods (Fig. 4B) . We found that although levels of CD25 detected with the same PC61 clone rapidly declined (<45 minutes), CD25 levels detected with a different anti-CD25 clone, 7D4, remained at normal levels for nearly 24 hours. These levels then began a gradual decline that mimicked exactly the time course of Foxp3 levels. Additionally, whereas rat IgG1 was not detectable on the surface of cells before in vivo PC61 administration, by 45 minutes after injection, its levels matched those of Foxp3 and 7D4, a pattern that continued out to 40 days. Both 7D4 and rat IgG1 were found specifically on the surface of Foxp3 + and GITR + cells (correlative surface presence of rat IgG1 and GITR shown in Fig. 4C ). Together, these data strongly suggest that the 
+ cells from anti-CD25 -treated animals failed to suppress the identical T-cell population (Fig. 4D) .
Although it seems then that anti-CD25 administration in vivo does elicit a limited decline in T regs , this depletion is clearly not comprehensive. Anti-CD25, however, does show the ability to functionally inactivate those T regs that persist at significant levels in vivo, thereby interfering with their ability to suppress T-cell proliferation.
T-cell function and antiglioma immunity following anti-CD25 administration. As anti-CD25 administration did seem to affect T reg function, we examined what effects systemic anti-CD25 administration might have on the general proliferative and IFN-g-elaborating capacities of T cells isolated from VM/Dk mice. To this end, we removed the spleens of VM/Dk mice 7 days following either anti-CD25 or isotype control antibody administration. Lymphocyte-enriched populations were isolated and cultured with a-CD3-and a-CD28-coated latex beads as stimulators. The proliferative response of cells was measured by [ 3 H]thymidine uptake whereas IFN-g elaboration was measured by ELISA. In vivo anti-CD25 significantly enhanced the ability of the lymphocyte compartment to proliferate (Fig. 5A ) and secrete IFN-g (Fig. 5B ) in response to polyclonal T-cell receptor stimulation.
Experiments were subsequently initiated to determine the ability of anti-CD25 to enhance glioma-specific CTL responses. T cells were initially primed in vivo with a dendritic cell vaccine targeting malignant glioma. Mice were given antiCD25 or an isotype control antibody 4 days before receiving a single s.c. vaccination with syngeneic dendritic cells electroporated with total tumor RNA isolated from the SMA-560 glioma cell line (DC-SMA). Vaccinations were delivered bilaterally at the base of each ear, in proximity to the cervical lymph nodes.
Ten days pursuant to vaccination, spleens from all mice were harvested and restimulated in vitro with DC-SMA. Splenocytes were then entered into a CTL assay using SMA-560 cells (H2K b ) and two control tumor cell lines, B16/F10.9 (H2K b ) and EL4 (H2K b ), as targets. DC-SMA vaccination alone produced a significant specific lysis of SMA-560 targets. This CTL response, however, was dramatically enhanced in those mice that received anti-CD25 before vaccination, in which specific lysis of glioma targets approached 80% (Fig. 5C ). Survival and experimental allergic encephalitis studies. The strength of the effects of anti-CD25 on in vitro T-cell responses and CTL-mediated tumor cell lysis led us to test whether the same antibody would be a successful adjunct to a dendritic cell -based immunization strategy targeting glioma in vivo. We therefore examined the effects of anti-CD25 alone, dendritic cell vaccination alone, or a combination of both therapies on the ability of mice to reject intracranial glioma challenge.
To this end, all dendritic cells were electroporated with total tumor RNA isolated from the SMA-560 glioma cell line, and all mice were challenged with 10,000 SMA-560 cells placed intracranially under stereotactic guidance. Mice receiving anti-CD25 were given a single i.p. injection of PC61 antibody 4 days before vaccination whereas controls received an equivalent dose of isotype control antibody. Vaccines were delivered 7 days before tumor challenge and were injected s.c. at the base of each ear. Anti-CD25 as a lone modality extended median survival and proved capable of rejecting tumor in 50% of treated mice (P = 0.0198, in comparison with PBS group). Vaccine alone also produced significant survival benefits (P = 0.0153; median survival, 31 days versus 17 days in PBS group), but combining this strategy with anti-CD25 therapy significantly enhanced its efficacy (P = 0.0486 for comparison with vaccine only group), evoking complete tumor rejection in all treated mice and eliciting 100% long-term survival (P = 0.0018, in comparison of combination group with PBS group; Fig. 6A ).
To convince ourselves of an immune-based mechanism for anti-CD25, we initiated a set of experiments to rule out a direct effect of anti-CD25 on the SMA-560 tumor. To begin, the SMA-560 cell line was tested for surface expression of CD25 by flow cytometry. No CD25 was detected (data not shown). Additionally, SMA-560 tumor cells were cultured in the presence of various doses of anti-CD25 antibody. No effects on either proliferation (Fig. 6B ) or cell viability (P = 0.9187; Fig. 6C ) were identified. Lastly, we examined the ability of anti-CD25 to elicit tumor rejection in immunocompromised mice. Anti-CD25 or isotype control antibody was administered in vivo in the same manner as above to athymic BALB/c mice, 4 days before intracranial challenge with 10,000 SMA-560 tumor cells. No effect on survival was elicited (P = 0.1875; Fig. 6D ). Together, these data indicate the absence of a direct effect of anti-CD25 antibody on SMA-560 and suggest instead an immune-dependent mechanism of action.
Successful attempts to remove barriers to immunity against tumors situated within the CNS not infrequently carry risks for instigating autoimmune reactions similar to experimental allergic encephalomyelitis (26) . Evidence supports an experimental allergic encephalitis-protective role for T regs (27, 28) , substantiating concerns associated with employing T reg ''depletion'' as an adjunct to brain-tumor directed immunotherapy. As anti-CD25 then seemed to enhance immune responses to glioma in VM/Dk mice, we evaluated the risk that such strengthened antitumor immunity might pose concomitantly for the precipitation of experimental allergic encephalitis.
VM/Dk mice are a strain susceptible to experimental allergic encephalitis, such that autoimmunity can be evoked by a single i.d. vaccination with MOG35-55 peptide in complete Freund's adjuvant ( Fig. 6E and F) . We therefore evaluated all mice in the above VM/Dk survival experiments for signs of experimental allergic encephalitis. No mice showed clinical signs of experimental allergic encephalitis and the absence of inflammation was confirmed histologically with staining of brain and spinal cord sections with H&E and luxol fast blue. Thus, anti-CD25 provided a powerful immune-based adjunct to dendritic cell vaccination and, despite being combined with a platform targeting shared tumor and CNS antigens, elicited no observable experimental allergic encephalitis in a susceptible mouse model.
Discussion
Cellular immune defects are frequently associated with malignancy and are particularly severe in patients with malignant glioma (18) . Increased T reg fractions among CD4 + T cells have presently been shown in patients harboring a variety of malignancies and are believed to play a role in hindering antitumor immunity (13 -16) . In patients with malignant glioma, such increased fractions in peripheral blood have been shown to correlate with the manifestation of the cellular immune defects typical for these patients, including impaired T-cell proliferative responses and counterproductive shifts toward TH2 cytokine production (17) . Given the immune impairments elicited by alterations to the T reg fraction, an appropriate murine cancer model for exploring T reg -directed interventions would be one in which similar alterations are aptly recapitulated. Thus, our studies here validate our murine model of malignant glioma as a suitable model for investigating means of manipulating the T reg pool and exploring T reg effects on antitumor immune function.
Specifically, we have found here that VM/Dk mice harboring syngeneic SMA-560 gliomas exhibit dramatic reductions in both CD4 and T reg counts in the peripheral blood, spleens, and in the tumor ipsilateral and contralateral cervical lymph nodes, where these changes were most dramatic. This mirrors the situation observed in the peripheral blood of patients with malignant glioma, as does the relative persistence of T regs as an increased fraction of the remaining CD4 + T-cell compartment despite their reduced numbers. It also suggests the cervical lymph nodes as a potentially important site for immune analysis in patients with malignant glioma.
It is noteworthy, however, that this scenario of increased T reg fractions and diminished CD4 and T reg counts is not extrapolated into the bone marrow, which reveals instead an apparent true expansion of T reg numbers in the tumor-bearing state despite harboring dramatic reductions in the T reg fraction among CD4 + cells. This apparent paradox is explained simply by the observation that an even larger expansion of the CD4 + CD25
À compartment occurs in the marrow, drowning the T reg increase. It is not yet clear whether these increases in CD4 and T reg numbers represent a retention of these cells or, On day À7, mice were vaccinated with 2.5 Â 10 5 dendritic cells electroporated with total tumor RNA from the SMA-560 glioma cell line or injected with an equivalent volume of PBS. Injections were delivered s.c. at the base of each ear. On day 0, all mice were challenged i.c. with10,000 syngeneic SMA-560 cells. Kaplan-Meier survival data are presented as the percentage of mice surviving in each group. Differences in survival were determined by log-rank test. Anti-CD25 (P = 0.0198) and dendritic cell vaccine (P = 0.0153) alone each produced significant survival benefits, but the combination of the two elicited 100% long-term survival (P = 0.0018). B and C, anti-CD25 has no direct antitumor effect in vitro. SMA-560 cells were cultured in the presence of various doses of anti-CD25 for 3 days; after which, proliferation was assessed by [ First, we observed a precipitous drop in CD25 + (PC61) cells and no change in the levels of CD4 + Foxp3 + GITR + cells in the immediate minutes and hours following anti-CD25 injection. Furthermore, our persistent ability to detect both the administered antibody (a rat IgG1 isotype) and an alternative epitope of CD25 (7D4) specifically on the surface of CD4 + Foxp3 + GITR + cells insinuates that these were indeed the same cells and that CD25 was neither entirely shed nor internalized, with at least some amount remaining on the cell surface bound by antibody. The continued presence of the anti-CD25 rat IgG1 on these cells may have effectively blocked CD25 detection and may also have been the impetus for an inefficient antibodydependent cell-mediated cytotoxicity -based depletion. This would likewise explain the slow but somewhat steady decline in CD4 + Foxp3 + GITR + cell number following anti-CD25 mAb injection.
We also provide a more direct demonstration that anti-CD25 administered in vivo may explicitly interfere with T reg function. Despite the paradigm shift, however, our results in this model show the safety and utility of an anti-CD25 strategy for the improvement of glioma-directed immunotherapy. Given resilient notions of CNS immune privilege (31 -33), the ability to generate a systemic antitumor immune response that is capable of extending itself into the CNS remains as a coveted goal of brain tumor immunotherapy. We find that systemic anti-CD25 mAb enhances T-cell proliferation and IFN-g elaboration, strengthens antigen-specific antiglioma CTL responses, and, most importantly, dramatically improves survival rates in a murine model of intracranial glioma without eliciting experimental allergic encephalitis. An immune-based mechanism for anti-CD25 is suggested, as the antibody fails to elicit direct antitumor effects or to eliminate tumor in immunocompromised athymic mice. Furthermore, the moderate survival benefit provided by anti-CD25 alone in our model (i.e., without pursuant dendritic cell vaccination) suggests that a spontaneous systemic physiologic immune response capable of targeting tumors in the CNS exists, and that peripheral T regs are important in attenuating this response. 
